Unity Biotechnology falls as eye disease treatment fails in mid-stage trial

Unity Biotechnology

24/03/2025 14:48

** Shares of Unity Biotechnology UBX.O fall 35.3% to $1.18

** Drug developer says its treatment for a type of eye disease failed to meet the main goal of a mid-stage trial

     ** Co was testing the treatment in patients with diabetic macular edema (DME), an eye condition that causes swelling in the retina in those who have poor vision despite prior treatment

** Co says the treatment, UBX1325, did not meet the main goal of statistical non-inferiority to Regeneron's REGN.O Eylea, the standard of care treatment for patients with DME

** Co, however, says UBX1325 showed improvements in clarity of vision of over 5 letters at weeks 24 and 36

** Co anticipates the complete results from the remaining patients in Q2 of 2025

** Stock had fallen 49.4% in 2024

 (Reporting by Sneha S K)

 ((Sneha.SK@thomsonreuters.com;))